↓ Skip to main content

Cancer Chemotherapy and Selective Drug Development

Overview of attention for book
Cover of 'Cancer Chemotherapy and Selective Drug Development'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Clinical Drug Resistance
  3. Altmetric Badge
    Chapter 2 New Therapies With Old Drugs
  4. Altmetric Badge
    Chapter 3 Antimetabolite Combinations Possessing Enhanced Efficacy
  5. Altmetric Badge
    Chapter 4 Mismatched Bone Marrow Transplantation
  6. Altmetric Badge
    Chapter 5 Prospects for Immunotherapy
  7. Altmetric Badge
    Chapter 6 Platinum Analogs
  8. Altmetric Badge
    Chapter 7 Mitoxantrone: A Promising New Agent for the Treatment of Human Cancer
  9. Altmetric Badge
    Chapter 8 Current Clinical Progress — Podophyllotoxins
  10. Altmetric Badge
    Chapter 9 Pharmacology of Nitrosourea Anticancer Agents
  11. Altmetric Badge
    Chapter 10 Current Clinical Progress with New Agents: Alkylating Agents
  12. Altmetric Badge
    Chapter 11 Interferon
  13. Altmetric Badge
    Chapter 12 Chemotherapy of Lung Cancer
  14. Altmetric Badge
    Chapter 13 Hormone-Chemotherapy in Treatment of Advanced Breast Cancer
  15. Altmetric Badge
    Chapter 14 Chemotherapy of Ovarian Cancer
  16. Altmetric Badge
    Chapter 15 Obstacles to Improved End-Results in Head and Neck Cancer
  17. Altmetric Badge
    Chapter 16 Treatment of Disseminated Malignant Lymphoma
  18. Altmetric Badge
    Chapter 17 Malignant Disease in Childhood
  19. Altmetric Badge
    Chapter 18 Chemotherapy of Disseminated Testicular Cancer
  20. Altmetric Badge
    Chapter 19 Rational Approach to the Management of Febrile Granulocytopenic Patients
  21. Altmetric Badge
    Chapter 20 Effective Use of Narcotic Analgesics
  22. Altmetric Badge
    Chapter 21 A Double Blind Cross-Over Study of Two Oral Formulations of Morphine
  23. Altmetric Badge
    Chapter 22 Non-Narcotics and Co-Analgesics
  24. Altmetric Badge
    Chapter 23 Advanced Cancer: Oncologist, Family Doctor, or Hospice?
  25. Altmetric Badge
    Chapter 24 Why Do Cancer Patients Vomit?
  26. Altmetric Badge
    Chapter 25 Cancer, Vomiting, and Gut Motility
  27. Altmetric Badge
    Chapter 26 The Medical Management of Malignant Bowel Obstruction
  28. Altmetric Badge
    Chapter 27 Etiology of Chemotherapy-Induced Vomiting
  29. Altmetric Badge
    Chapter 28 The Management of Nausea and Vomiting Caused by Anticancer Chemotherapy
  30. Altmetric Badge
    Chapter 29 Experimental Models and their Predictive Value in New Drug Development: A Critical Appraisal: I. Toxicity Models.
  31. Altmetric Badge
    Chapter 30 In Vivo Antitumor Models and Drug Development
  32. Altmetric Badge
    Chapter 31 Assays for Clonogenic Human Tumour Cells in Experimental and Clinical Chemotherapy
  33. Altmetric Badge
    Chapter 32 Mechanisms of Resistance to Anticancer Agents
  34. Altmetric Badge
    Chapter 33 The Role of Pharmacokinetics in Drug Design and Use
  35. Altmetric Badge
    Chapter 34 Novel Structures in Development
  36. Altmetric Badge
    Chapter 35 Hypoxia-Mediated Drugs for Radio- and Chemotherapy
  37. Altmetric Badge
    Chapter 36 Induction of Cell Differentiation as a Target for Cancer Therapy
  38. Altmetric Badge
    Chapter 37 Complement Lysis of Tumour Cells Induced by Univalent Antibodies
  39. Altmetric Badge
    Chapter 38 Antibody-Toxin Conjugates as Anti-Cancer Agents
  40. Altmetric Badge
    Chapter 39 Biological Response Modifiers as Anticancer Agents
  41. Altmetric Badge
    Chapter 40 Prostaglandins and Cancer — Therapeutic Potential
  42. Altmetric Badge
    Chapter 41 The Therapeutic Potential of Lymphokines in Human Cancer
  43. Altmetric Badge
    Chapter 42 The Interleukins
  44. Altmetric Badge
    Chapter 43 The Role of Polyamines in Cell Differentiation
  45. Altmetric Badge
    Chapter 44 Polyamines, Immune Response and Tumour Growth Control
  46. Altmetric Badge
    Chapter 45 Potential Use of Retinoids in Cancer Prevention and Treatment
  47. Altmetric Badge
    Chapter 46 Inosine 5’-Phosphate Dehydrogenase as a Target for Cancer Chemotherapy. Results with 3-Deazaguanine, Tiazofurin and 2- β -D-Ribofuranosylselenazole-4-Carboxamide (PD-111232)
  48. Altmetric Badge
    Chapter 47 Antitumour Activity and Pharmacology of CCRG 81010 (NSC 353451, M&B 39565, 8-carbamoyl-3-(1-chloroethyl)imidazo [5,1-d]-1,1,3,5-tetrazin-4(3H)-one)
  49. Altmetric Badge
    Chapter 48 New Pyrimidine Nucleosides with Potent Antiviral Activity
  50. Altmetric Badge
    Chapter 49 Lipophilic Inhibitors of Dihydrofolate Reductase
  51. Altmetric Badge
    Chapter 50 Review of Phase I-II Clinical Trials with Vinzolidine (VZL), A New Orally Active Semisynthetic Vinblastine Derivative
  52. Altmetric Badge
    Chapter 51 New Developments in Anthracyclines
  53. Altmetric Badge
    Chapter 52 Nitrosoureas-Still a Challenge for Developmental Cancer Chemotherapy
  54. Altmetric Badge
    Chapter 53 Further Objectives in the Development of Platinum Drugs
  55. Altmetric Badge
    Chapter 54 The Structure of Active Genes and HMG Proteins in Normal and Transformed Cells
  56. Altmetric Badge
    Chapter 55 Pretreatment of Human Colon Tumor Cells with DNA Methylating Agents Inhibits their Ability to Prevent Chloroethylnitrosourea-Induced DNA Interstrand Crosslinking
  57. Altmetric Badge
    Chapter 56 Structural Requirements for DNA Intercalation and their Relevance to Drug Design
  58. Altmetric Badge
    Chapter 57 Dialkanesulphonates and Chromatin
  59. Altmetric Badge
    Chapter 58 DNA Repair Characteristics of Walker Rat Carcinoma Cells Sensitive and Resistant to Cis -Diamminedichloroplatinum(II) (Cisplatin) and Difunctional Alkylating Agents
  60. Altmetric Badge
    Chapter 59 Is Alkylating Agent “Priming” a DNA Repair Phenomenon?
  61. Altmetric Badge
    Chapter 60 DTIC Induces Damage in Melanoma DNA During Semi-Conservative DNA Synthesis
  62. Altmetric Badge
    Chapter 61 The Non-Random Binding of Chlorambucil to DNA in Chromatin
  63. Altmetric Badge
    Chapter 62 Alkylating Antitumour Agents Decrease Histone Acetylation in Ehrlich-Ascites Tumour Cells
  64. Altmetric Badge
    Chapter 63 Influence of the Nuclear Matrix on Nuclear Structure and Response to Anticancer Drugs
  65. Altmetric Badge
    Chapter 64 Cytotoxicity of a Steroid-Linked Mustard (Estramustine) through Non-DNA Targets
  66. Altmetric Badge
    Chapter 65 Potentiation of Cytotoxicity by Inhibitors of Nuclear ADP-Ribosyl Transferase
  67. Altmetric Badge
    Chapter 66 Adjuvant Tamoxifen Treatment in Operable Breast Cancer. Should the Treatment Continue for Many Years?
  68. Altmetric Badge
    Chapter 67 Adjuvant Hormonal Therapy of Breast Cancer
  69. Altmetric Badge
    Chapter 68 New Approaches to the Use of Endocrine Therapy in Breast Cancer
  70. Altmetric Badge
    Chapter 69 The Pharmacology of a New Antiestrogen
  71. Altmetric Badge
    Chapter 70 In Vitro Systems for Evaluating Anti-Endocrine Agents
  72. Altmetric Badge
    Chapter 71 Experience of the LHRH Analogue, ICI 118,430, in Carcinoma of the Prostate
  73. Altmetric Badge
    Chapter 72 Complete Androgen Neutralization is Most Important in the Treatment of Prostate Cancer
  74. Altmetric Badge
    Chapter 73 Aminoglutethimide (Orimeten R ): The Present and the Future
  75. Altmetric Badge
    Chapter 74 The Development of New Anti-Endocrine Type Drugs
  76. Altmetric Badge
    Chapter 75 Antiestrogenic Action of Tamoxifen Derivatives in the Human Mammary Carcinoma Cell Line MCF-7
  77. Altmetric Badge
    Chapter 76 Nuclear Estrogen Receptors in Human Tumours of Breast and Uterus
  78. Altmetric Badge
    Chapter 77 Activation and Translocation of Estradiol Receptors in Nitrosomethylurea-Induced Mammary Carcinomas of Rats
  79. Altmetric Badge
    Chapter 78 Hormone Receptors in Gynecological Tumours and their Relevance for Therapeutic Management
  80. Altmetric Badge
    Chapter 79 Pretherapeutic in Vitro Prediction of Human Tumour Drug Response
  81. Altmetric Badge
    Chapter 80 Continuous Cell Lines as an Experimental Model for Bladder Cancer Chemotherapy
  82. Altmetric Badge
    Chapter 81 Chemical and Biological Properties and Mode of Action of 8-Carbamoyl-3-(2-Chloroethyl)Imidazo [5,1-d]-1,2,3,5-Tetrazin-4(3H)-One, A Novel Broad Spectrum Antitumour Agent
  83. Altmetric Badge
    Chapter 82 Lycurim in Combination Chemotherapy with 3,4,5-Trihydroxybenzo Hydroxamic Acid in Vitro
  84. Altmetric Badge
    Chapter 83 Phenotypic and Genotypic Changes Induced by Thioproline in Cancer Cells in Tissue Culture. Guidelines for Clinical Studies of the Drug
  85. Altmetric Badge
    Chapter 84 Use of Mesna in Reducing Bladder Toxicity
  86. Altmetric Badge
    Chapter 85 Normal Tissue Protection during High-Dose Chemo/Radiotherapy by a “Priming Dose” of Cyclophosphamide
  87. Altmetric Badge
    Chapter 86 5-Acetoxy-2-(4-Acetoxyphenyl)-1-Ethyl-3-Methylindole (D 16726): Preclinical Evaluation of a New Mammary Tumour Inhibiting Drug
  88. Altmetric Badge
    Chapter 87 Rolin Enhancing Effect Upon in Vitro PHA-Proliferation Of Normal Human Peripheral Blood Lymphocytes
  89. Altmetric Badge
    Chapter 88 DTIC: Towards an Appropriate Alternative
  90. Altmetric Badge
    Chapter 89 Drug Resistance of Human Glioma Cell Lines in Culture — The Role of Membrane Transport
  91. Altmetric Badge
    Chapter 90 Lethal and Kinetic Effects of AMSA in a Range of Human Tumour Cell Lines and its Value in Overcoming Induced Drug Resistance in a Series of Murine L5178Y Lymphoma Sublines in Vitro
  92. Altmetric Badge
    Chapter 91 A Novel HPLC Procedure for Measurement of 6-Mercaptopurine in Plasma
  93. Altmetric Badge
    Chapter 92 Potentiation of the Cytotoxicity of Antibody-Toxin a Chain Conjugates
  94. Altmetric Badge
    Chapter 93 The Effect of Inhibitors of Poly(ADP-Ribose)Polymerase Activity on the Cytotoxic Action of Bifunctional Alkylating Agents and Radiation
  95. Altmetric Badge
    Chapter 94 Characterisation of a Murine Renal Cell Carcinoma Model Potentially Useful in Selecting New Chemotherapeutic Agents
  96. Altmetric Badge
    Chapter 95 Perturbation of S-Adenosylhomocysteine (SAH) and S-Adenosylmethionine (SAM) Levels Following 2’-Deoxycoformycin (dCf) and 2’-Deoxyadenosine (AdR) Administration
  97. Altmetric Badge
    Chapter 96 The Development of Resistance to Methotrexate in a Human Leukaemia (AML) Growing in Nude Mice
  98. Altmetric Badge
    Chapter 97 Inhibitors of Thymidine (TdR) Salvage
  99. Altmetric Badge
    Chapter 98 Studies on the Mechanism of CB 3717 Induced Hepatotoxicity
  100. Altmetric Badge
    Chapter 99 Studies Relating to the Reversal of the Cytotoxicity of the Thymidylate Synthetase Inhibitor CB 3717
  101. Altmetric Badge
    Chapter 100 Studies with Mutant L1210 Cell Lines that have Acquired Resistance to CB 3717
  102. Altmetric Badge
    Chapter 101 PAC Polychemotherapy of Stage III + IV Ovarian Carcinoma
  103. Altmetric Badge
    Chapter 102 Weekly Low Dose 4 Epi-Adriamycin-Effective Single Agent Chemotherapy for Advanced Breast Cancer with Low Toxicity
  104. Altmetric Badge
    Chapter 103 Combination Treatment of Malignant Gliomas with Dibromodulcitol (DBD)
  105. Altmetric Badge
    Chapter 104 Initial Clinical Sudies with Iproplatin (CHIP, JM9)
  106. Altmetric Badge
    Chapter 105 Tamoxifen Induced Fluorescence: Spectrofluorimetric Study and Clinical Applications of the Ion-Pair Eosin Tamoxifen
  107. Altmetric Badge
    Chapter 106 EB-Virus Antibody Titers in Two Sisters with Nasopharyngeal Carcinoma and in Several Members of their Family
  108. Altmetric Badge
    Chapter 107 Loco-Regional Chemotherapy with Adriamycin — Intravesical, Intrapleural, and Intrahepatic Administration
  109. Altmetric Badge
    Chapter 108 Etoposide (VP 16–213) as a Fourth Drug in Combination with BVP for Treating Metastatic Germ Cell Tumours
  110. Altmetric Badge
    Chapter 109 Investigations on Leucovorin Rescue after Methotrexate Treatment of Human Osteosarcoma Cells in vitro
  111. Altmetric Badge
    Chapter 110 Early Clinical Studies with CB 3717 (N-(4-(N-((2-Amino-4-Hydroxy-6-Quinazolinyl)Methyl)Prop-2-Ynylamino)Benzoyl)-L-Glutamic Acid) at the Royal Marsden Hospital
  112. Altmetric Badge
    Chapter 111 DNA Repair Enzymes and Crosslinks: Prevention of BCNU Inter-Strand Crosslinking in vitro by 06-Methyltransferase
  113. Altmetric Badge
    Chapter 112 CIS-Diamminedichloroplatinum Toxicity and DNA Crosslinking in Human Melanoma and Lymphoblast Cells
  114. Altmetric Badge
    Chapter 113 Experimental Trial of New Alkylating Hexitols
  115. Altmetric Badge
    Chapter 114 Sites and Extents of Alkylation in Tumour Cell DNA and their Relation to Antitumour Effects of Dibromodulcitol and Dianhydrogalactitol
  116. Altmetric Badge
    Chapter 115 Hexamethylmelamine: Metabolic Activation and Cytotoxicity
  117. Altmetric Badge
    Chapter 116 Melanogenesis in Human Malignant Melanoma Xenografts
  118. Altmetric Badge
    Chapter 117 DNA Cross-Linking and Cytotoxicity in Normal and Transformed Human Cells Treated in vitro with M&B 39565
  119. Altmetric Badge
    Chapter 118 In Vivo Pharmacokinetics of Daunorubicin in Bone Marrow in Adult Acute Nonlymphocytic Leukaemia
  120. Altmetric Badge
    Chapter 119 Pharmacologic Characterization of Teroxirone (Henkel Compound) in Animals and Humans
  121. Altmetric Badge
    Chapter 120 Pharmacokinetics and Toxicity of VP 16 (Etoposide) in Patients with Gestational Choriocarcinoma and Malignant Teratoma
  122. Altmetric Badge
    Chapter 121 Tissue Distribution and Myelotoxicity of Daunomycin in Normal and Leukemic Rats: Rapid Bolus Injection versus Continuous Infusion
  123. Altmetric Badge
    Chapter 122 Metabolism of 4-Hydroxyandrostene-3, 17-Dione by Rat Liver
  124. Altmetric Badge
    Chapter 123 Enzyme Inhibition Studies with Derivatives of Aminoglutethimide
  125. Altmetric Badge
    Chapter 124 The Species Dependent Pharmacokinetics of DTIC
  126. Altmetric Badge
    Chapter 125 Preliminary Studies on the Metabolism and Pharmacokinetics of the Dialkylphenyltriazenes
  127. Altmetric Badge
    Chapter 126 The Role of Glutathione and Glutathione S-Transferases in Acquired Drug Resistance
  128. Altmetric Badge
    Chapter 127 Disposition of Tricyclic Nucleoside 5’-Phosphate (TCN-P, NSC 280594) in Man and Rat
  129. Altmetric Badge
    Chapter 128 Circadian Variation in the Pharmacokinetics of Some Cytotoxic Drugs and Synthetic Steroids
  130. Altmetric Badge
    Chapter 129 Antitumour and Pharmacokinetic Studies with Platinum Coordination Complexes Following Oral Administration
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

wikipedia
3 Wikipedia pages

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cancer Chemotherapy and Selective Drug Development
Published by
Springer Science & Business Media, December 2012
DOI 10.1007/978-1-4613-3837-6
ISBNs
978-1-4613-3837-6, 978-1-4613-3839-0
Editors

Harrap, K. R., Davis, W., Calvert, A. H.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 1 100%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 100%